Yaupon Therapeutics Adds $14.4M Series D
Malvern, Penn.-based Yaupon Therapeutics Inc. has closed on $14.4 million in Series D financing. The company, a specialty pharmaceutical maker, is backed by Vivo Ventures, Palo Alto Investors, Burrill & Company and Aperture Venture Partners. The new funds will help the company go through the regulatory review process for a drug designed to treat early stage mycosis fungoides, the most common type of cutaneous T-cell lymphoma.
11 August 2011•2 mins read
